Reduced-Antigen, Combined Diphtheria, Tetanus, and Acellular Pertussis Vaccine (Boostrix™)
- 61 Downloads
Reduced-antigen, combined diphtheria, tetanus, and acellular pertactin-containing pertussis vaccine (dTpa; Boostrix™) contains reduced quantities of the same toxoids/antigens found in a diphtheria, tetanus, and acellular pertussis vaccine (DTPa; Infanrix™) used for the primary immunization series in children. A single dose of dTpa (Boostrix™) is indicated for booster vaccination against diphtheria, tetanus, and pertussis in individuals aged ≥4 years in Europe and Canada, in individuals aged ≥10 years in Australia, and in adolescents aged 10–18 years in the US.
A single booster dose of dTpa (Boostrix™) was safe and highly immunogenic for all its component toxoids/antigens when administered to adults, adolescents (including those previously unvaccinated), and children aged ≥4 years in clinical trials conducted in various countries worldwide. It was also well tolerated, as was a second (repeat) dose administered to a small number of adolescents who had previously received the vaccine as a preschool booster. Vaccinees generally reported a low incidence of severe/grade 3, solicited, local and general adverse events during the 1-month postvaccination period.
Current recommendations for dTpa usage vary from country to country; they include one dose only in adolescence or adulthood (e.g. Australia, Canada, France, Switzerland, and the US), one dose at preschool age and one in adolescence (Germany), and one dose in adolescence followed by regular (10-year) doses during adulthood (Austria). Available data support the use of dTpa (Boostrix™) in place of the combined diphtheria, tetanus, whole-cell pertussis vaccine (DTwP) or DTPa booster dose in preschool children and/or the reduced-antigen, combined diphtheria, tetanus vaccine (Td) booster dose in adolescents, as well as in place of a regular Td booster dose in adults who have not previously received the vaccine.
Each 0.5mL dose of dTpa (Boostrix™) contains 2.5 limits of flocculation (Lf) of diphtheria toxoid, 5Lf of tetanus toxoid, 8μg of pertussis toxoid (PT), 8μg of filamentous haemagglutinin (FHA), and 2.5μg of pertactin (PRN).
Numerous studies in preschool and older children, as well as in adolescents and adults, have demonstrated that a single dose of dTpa (Boostrix™), administered by deep intramuscular injection, is highly immunogenic for all its component toxoids and antigens, regardless of subjects’ prior vaccination history and pre-vaccination serologic status. One month after administration of the vaccine, ≥88.4% and ≥96.7% of subjects had seroprotective titers (≥0.1 IU/mL by ELISA and/or ≥0.016 IU/mL by Vero cell assay) of anti-diphtheria toxoid (anti-D) and anti-tetanus toxoid (anti-T) antibodies, respectively; ≥90.2%, ≥99.3%, and ≥96.3% of subjects had seropositive levels (≥5 ELISA U/mL) of anti-PT, anti-FHA, and anti-PRN antibodies, respectively. A single dose of dTpa (Boostrix™) was also immunogenic when administered to previously unvaccinated adolescents with no history of pertussis and low anti-PT antibody levels. Most differences in antibody responses to diphtheria and tetanus toxoids, as well as those to pertussis antigens, were not statistically and/or clinically significant when dTpa (Boostrix™) formulations containing 0.5mg adjuvant aluminum (as per the non-US formulation) and 0.3mg adjuvant aluminum (as per the US-only formulation) were directly compared in adolescents.
The immunogenicity 1 month postvaccination of a single dose of dTpa (Boostrix™) was similar to that of a fifth dose of DTwP or DTPa (Infanrix™) in preschool children, and similar to that of a single dose of another dTpa vaccine (Adacel™) in adolescents who had previously received three doses of DTwP and a booster dose of combined diphtheria and tetanus-containing vaccine. Likewise, the immunogenicity of dTpa (Boostrix™) in adolescents and adults was similar to that of its acellular pertussis (ap) component in terms of anti-pertussis antibody responses, and similar to that of several Td booster vaccines (each containing slightly different amounts of diphtheria and tetanus toxoids) in terms of anti-D and anti-T seroprotection rates. dTpa (Boostrix™) met the predefined criteria for non-inferiority to Td based on seroprotection and booster response rates to diphtheria and tetanus toxoids in a large study of >4100 US adolescents.
Long-term persistence of seroprotective titers of anti-D and anti-T antibodies and of seropositive levels of all three anti-pertussis antibodies has been observed ≥3 years after administration of dTpa (Boostrix™) in preschool children, adolescents, and adults.
The protective efficacy of dTpa (Boostrix™) has not been evaluated, although postvaccination anti-pertussis antibody geometric mean concentrations in the large study in US adolescents were non-inferior to and, moreover, numerically higher than those previously proven to be effective in infants who completed a three-dose primary vaccination course with DTPa (Infanrix™). The ap component of dTpa (Boostrix™) demonstrated an overall vaccine efficacy of 92% in a large, well designed trial in adolescents and adults.
A single dose of dTpa (Boostrix™) was non-inferior to a monovalent tetanus toxoid vaccine with respect to providing tetanus prophylaxis in the context of emergency room, tetanus-prone wound management.
A single 0.5mL dose of dTpa (Boostrix™; US or non-US formulation) administered to children, adolescents, and adults was shown to be safe and well tolerated in clinical trials. The tolerability of dTpa (Boostrix™) in terms of solicited local reactions (pain, redness, and swelling at the injection site) and general adverse events (fatigue, gastrointestinal symptoms, headache, and fever) was largely similar across all three age groups, and characterized by a generally low incidence of grade 3/severe symptoms. The majority of solicited symptoms occurred within 48–72 hours of vaccination with dTpa (Boostrix™), and were of mild intensity and short duration; all resolved spontaneously within the 15-day postvaccination period without sequelae. The incidence of large injection site swelling (LISS) was generally very low (<1%), including in a study of adolescents in Germany who received dTpa (Boostrix™) for the first or second time (as a sixth consecutive dose of ap-containing vaccine). No serious adverse events (SAEs) considered to be related to vaccination were reported within the 31-day postvaccination period in children, adolescents or adults; no SAEs that were of potential autoimmune origin or of new onset and chronic in nature were reported during long-term (6-month) follow-up of adolescent vaccinees in Germany and the US. Lowering the adjuvant aluminum content of dTpa (Boostrix™) from 0.5mg per 0.5mL dose (as per the non-US formulation) to 0.3mg per 0.5mL dose (in line with the US-only formulation) had little impact on its reactogenicity.
When administered to preschool children, dTpa (Boostrix™) was better tolerated than a fifth dose of DTwP and at least as well tolerated as a fifth dose of DTPa (Infanrix™). dTpa (Boostrix™) was as well tolerated as another dTpa vaccine (Adacel™) in adolescents who had previously received four doses of combined diphtheria and tetanus-containing vaccine, and was as well tolerated as, or non-inferior to, licenced Td vaccines when administered to preschool children, adolescents, or adults. Due to the additional presence of the tetanus and diphtheria toxoids, dTpa (Boostrix™) was less well tolerated than its ap component in terms of solicited local symptoms when administered to adults; however, similar incidences of general symptoms in adults and of individual local or general symptoms in adolescents were seen with these vaccines.
KeywordsPertussis dTpa Diphtheria Tetanus Toxoid Seroprotection Rate
- 1.U.S. Department of Health and Human Services. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures recommendations of the immunization practices advisory committee (ACIP). MMWR Recomm Rep 1991 Aug 8; 40 (RR10): 1–28Google Scholar
- 4.Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006 Mar 24; 55 (RR-3): 1–34Google Scholar
- 10.World Health Organisation. Diphtheria toxoid [online]. Available from URL: http://www.who.int/immunization/topics/diphtheria/en/index.html [Accessed 2006 Jul 28]
- 11.Di Pasquale A, Wolter J, Schuerman L, et al. Management of pertussis in adolescents and adults: the role of a reduced-antigen content combined diphtheria-tetanus-acellular pertussis (dTpa) vaccine. J Prevent Med Hyg 2005; 46: 33–41Google Scholar
- 12.Centers for Disease Control and Prevention. Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five-dose series: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49 (RR-13): 1–8Google Scholar
- 14.GlaxoSmithKline. Boostrix (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed): precribing information. Research Triangle Park (NC): GlaxoSmithKline, 2006 FebGoogle Scholar
- 15.GlaxoSmithKline. Boostrix™: summary of product characteristics. Research Triangle Park (NC): GlaxoSmithKline, 2004 Jul 6Google Scholar
- 16.Aventis Pasteur Limited. Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed. ADACEL™: prescribing information. Swiftwater (PA): Aventis Pasteur Limited, 2005, Swiftwater (PA) JGoogle Scholar
- 17.GlaxoSmithKline Australia Pty Ltd. Boostrix® product information. Boronia: GlaxoSmithKline Australia Pty, 2003 Nov 12Google Scholar
- 20.GlaxoSmithKline. Diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed. Infanrix®: prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2003 AugGoogle Scholar
- 22.Zepp F, Cheuvart B, Wolter JM. Anti-diphtheria antibodies should persist until adolescence after a reduced-antigen diphtheria, tetanus and acellular pertussis vaccine (DTPA) in pre-school-aged children [abstract no. 281.00 plus poster]. 21st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID); 2003 Apr 9–11; Taormina, SicilyGoogle Scholar
- 23.Kosuwon P, Warachit B, Hutagalung Y, et al. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4–6 year-old children primed with four doses of whole-cell pertussis vaccine. Vaccine 2003 Oct 1; 21(27–30): 4194–200PubMedCrossRefGoogle Scholar
- 39.Schmitt H-J, Schuind A, Knuf M, et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. J Pediatr 1996 Nov; 129(5): 696–701Google Scholar
- 42.Dubey AP, Bose DJ, Ghandi A, et al. Safety and reactogenicity of a booster formulation diphtheria-tetanus-acellular pertussis vaccine in Indian children [abstract no. ID/43(P)]. 43rd National Conference of Indian Academy of Pediatrics; 2006 Jan 5–8; New DelhiGoogle Scholar
- 44.Schwartz AT. FDA clinical briefing document for GlaxoSmithKline Biologicals tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, adsorbed Boostrix™ [online]. Available from URL: http://www.fda.gov [Accessed 2006 Feb 27]
- 45.Robert Koch Institut. Epidemiologisches Bulletin nr. 3 Empfehling der Ständigen Impfkommission (STIKO) am Robert Koch-Institut zur pertussisschutzimpfung stand: Nr. 30 [online]. Available from URL: http://www.rki.de [Accessed 2006 Nov 27]
- 46.Department of Health Government of Western Australia. Adult diphtheria-tetanus-pertussis vaccine dTpa (Boostrix™) year 7 primary school students [online]. Available from URL: http://www.population.health.wa.gov.au/communicable/resources/ACF9BE.pdf [Accessed 2006 Nov 22]
- 47.Calendrier vaccinal 2006 avis du conseil supérieur d’hygiène publique de France. No. 29-30 [online]. Available from URL: http://www.invs.sante.fr/BEh/2006/29_30/index.htm [Accessed 2006 Nov 27]
- 49.World Health Organisation. Pertussis vaccine [online]. Available from URL: http://www.who.int [Accessed 2006 Jul 31]
- 55.Wirsing von Koni C-H, Campins-Marti M, Finn A, et al. Pertussis immunisation in the global pertussis initiative European region: recommended strategies and implementation considerations. Pediatr Infect Dis J 2005; 24(5): S87–92Google Scholar
- 57.Caro JJ, Getsios D, El-Hadi W, et al. Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis J 2005 May; 24Suppl. 5: 75–82Google Scholar
- 62.Robert Koch Institut. Epidemiologisches Bulletin nr. 3 Empfehling der Ständigen Impfkommission (STIKO) am Robert Koch-Institut zur pertussisschutzimpfung stand: Nr 3. [online]. Available from URL: http://www.rki.de [Accessed 2006 Aug 4]
- 63.National Health and Medical Research Council. The Australian immunisation handbook. 8th ed. Canberra: Australian Government Department of Health and Aging, 2003Google Scholar
- 64.National Advisory Committee on Immunization (NACI). Prevention of pertussis in adolescents and adults. Can Commun Dis Rep 2003 Sep 1; 29 (ACS 5, 6): 1–9Google Scholar
- 65.Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule: United States, 2006. MMWR 2006 Jan 6; 54: Ql–4Google Scholar
- 66.Centers for Disease Control and Prevention. ACIP votes to recommend use of combined tetanus, diphtheria and pertussis (Tdap) vaccine for adults [online]. Available from URL: http://www.cdc.gov/nip/vaccine/tdap/tdap_adult_recs.pdf [Accessed 2006 Jul 1]
- 67.Public Health Agency of Canada. Vaccine-preventable diseases: pertussis [online]. Available from URL: http://www.phac-aspc.gc.ca [Accessed 2006 Aug 2]
- 68.Public Health Agency of Canada. Vaccine-preventable diseases: diphtheria [online]. Available from URL: http://www.phac-aspc.gc.ca [Accessed 2006 Aug 2]
- 73.Vergara R, Tregnaghi M, Ussher J, et al. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr 2005 Mar 22Google Scholar